A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Destiny Pharma
Ticker: DEST Exchange: AIM www.destinypharma.com

Destiny Pharma is dedicated to the discovery, development and commercialisation of new antimicrobials that have unique properties to improve outcomes for patients and the delivery of medical care into the future.

Destiny Pharma 12 Apr 2022

Results bring welcome detail and no surprises

After the recent fundraising, there were no surprises in Destiny’s FY 2021 financials which...

Read more
Destiny Pharma 29 Mar 2022

NTCD-M3 competitors stumble while issue approved

With the recently announced fundraising approved at Destiny’s GM, and the competition to Destiny’s...

Read more
Destiny Pharma 09 Mar 2022

Fundraising to bolster its positioning

Destiny have announced a conditional fundraising at 50p per share that includes a placing,...

Read more
Destiny Pharma 08 Feb 2022

Very welcome regulatory clarity

Destiny Pharma has announced details of positive feedback from the European Medicines Agency (EMA)...

Read more
Destiny Pharma 25 Jan 2022

M3’s profile rising further

In a spree of positive updates to start 2022, Destiny Pharma begins the year with the profile of...

Read more
Destiny Pharma 08 Nov 2021

Support on both fronts

Destiny’s most recently acquired Phase 3-ready product, the non-toxigenic Clostridioides difficile...

Read more
Destiny Pharma 27 Sep 2021

New dermal collaboration on XF-73

Destiny Pharma has announced a new clinical programme that is planned to start in China, led by its...

Read more
Destiny Pharma 09 Sep 2021

H1 2021 interims: still on track

Destiny's interim H1 2021 financial results were an upbeat and extensive update on the clinical...

Read more
Destiny Pharma 02 Aug 2021

XF-73 data maturing, like a fine wine

Destiny have released additional endpoint analyses after the positive headline announcement of the...

Read more
Destiny Pharma 02 Jul 2021

A glaring differential in validation

Recent transactions and the introduction of a new Act of the US Congress are further advancing the...

Read more
Destiny Pharma 07 Jun 2021

Encouraging AGM and M3 updates

Destiny’s recent announcement on the progress on its lead asset NTCD-M3 maintains the momentum that...

Read more
  • 1 of 3 pages

Register to be first

Get research on the companies that interest you straight to your inbox

Register For Updates